☰

Han K. Ho, Ph.D. - Publications

Affiliations: 
2005 University of Washington, Seattle, Seattle, WA 
Area:
Toxicology, Cell Biology
Tree Info Similar researchers PubMed Report error

39 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Goh ZH, Tee JK, Ho HK. An Evaluation of the In Vitro Roles and Mechanisms of Silibinin in Reducing Pyrazinamide- and Isoniazid-Induced Hepatocellular Damage. International Journal of Molecular Sciences. 21. PMID 32466226 DOI: 10.3390/Ijms21103714  0.345
2020 Koh YQ, Tan CJ, Toh YL, Sze SK, Ho HK, Limoli CL, Chan A. Role of Exosomes in Cancer-Related Cognitive Impairment. International Journal of Molecular Sciences. 21. PMID 32326653 DOI: 10.3390/Ijms21082755  0.303
2019 Tee JK, Yip LX, Tan ES, Santitewagun S, Prasath A, Ke PC, Ho HK, Leong DT. Nanoparticles' interactions with vasculature in diseases. Chemical Society Reviews. PMID 31495856 DOI: 10.1039/C9Cs00309F  0.312
2019 Yap N, Ho H, Zheng H, Tan C, Toh Y, Ng C, Chan A. An in vitro evaluation of CYP2D6 enzymatic inhibition activities of a Chinese herbal medicine formulation (Xiang Bei Yangrong Tang) for the management of cancer-related fatigue Annals of Oncology. 30: ix143. DOI: 10.1093/Annonc/Mdz434.012  0.311
2018 Tee JK, Ng LY, Koh HY, Leong DT, Ho HK. Titanium Dioxide Nanoparticles Enhance Leakiness and Drug Permeability in Primary Human Hepatic Sinusoidal Endothelial Cells. International Journal of Molecular Sciences. 20. PMID 30577655 DOI: 10.3390/Ijms20010035  0.308
2018 Tee JK, Peng F, Tan YL, Yu B, Ho HK. Magnesium Isoglycyrrhizinate Ameliorates Fibrosis and Disrupts TGF-β-Mediated SMAD Pathway in Activated Hepatic Stellate Cell Line LX2. Frontiers in Pharmacology. 9: 1018. PMID 30319402 DOI: 10.3389/Fphar.2018.01018  0.324
2018 Peng F, Tee JK, Setyawati MI, Ding X, Yeo HLA, Tan YL, Leong DT, Ho HK. Inorganic Nanomaterials as Highly Efficient Inhibitors of Cellular Hepatic Fibrosis. Acs Applied Materials & Interfaces. PMID 30156820 DOI: 10.1021/Acsami.8B10527  0.303
2018 Chae JW, Chua PS, Ng T, Yeo AHL, Shwe M, Gan YX, Dorajoo S, Foo KM, Loh KW, Koo SL, Chay WY, Tan TJY, Beh SY, Lim EH, Lee GE, ... ... Ho HK, et al. Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study. Breast Cancer Research and Treatment. PMID 29313215 DOI: 10.1007/S10549-017-4640-7  0.307
2017 Chae J, Chua PS, NG T, Yeo HLA, Shwe M, Gan YX, Dorajoo SR, Foo KM, Loh KWJ, Koo S, Chay WY, Tan TJY, Beh SY, Lim HE, Lee GE, ... ... Ho HK, et al. Mitochondrial DNA content in peripheral blood as a biomarker for cancer-related fatigue in early-stage breast cancer patients: A prospective cohort study. Journal of Clinical Oncology. 35: 10018-10018. DOI: 10.1200/Jco.2017.35.15_Suppl.10018  0.308
2016 Pang YY, Tan YM, Chan EC, Ho HK. Phase I metabolic stability and electrophilic reactivity of 2-phenylaminophenylacetic acid derived compounds. Chemical Research in Toxicology. PMID 27245204 DOI: 10.1021/Acs.Chemrestox.6B00042  0.317
2015 Ngai MH, So CL, Sullivan MB, Ho HK, Chai CL. Photoinduced Isomerization and Hepatoxicities of Semaxanib, Sunitinib and Related 3-Substituted Indolin-2-ones. Chemmedchem. PMID 26593399 DOI: 10.1002/Cmdc.201500475  0.315
2015 Tang SQ, Lee YY, Packiaraj DS, Ho HK, Chai CL. A Systematic Evaluation of the Metabolism and Toxicity of Thiazolidinone and Imidazolidinone Heterocycles. Chemical Research in Toxicology. PMID 26401548 DOI: 10.1021/Acs.Chemrestox.5B00247  0.323
2015 Ho HK, Chan JC, Hardy KD, Chan EC. Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib. Drug Metabolism Reviews. 47: 21-8. PMID 25639891 DOI: 10.3109/03602532.2014.1003648  0.304
2015 Teo YL, Ho HK, Chan A. Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review. Expert Opinion On Drug Metabolism & Toxicology. 11: 231-42. PMID 25400226 DOI: 10.1517/17425255.2015.983075  0.319
2015 Teo YL, Ho HK, Chan A. Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. British Journal of Clinical Pharmacology. 79: 241-53. PMID 25125025 DOI: 10.1111/Bcp.12496  0.311
2014 Teo YL, Chue XP, Chau NM, Tan MH, Kanesvaran R, Wee HL, Ho HK, Chan A. Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib. Targeted Oncology. PMID 25502986 DOI: 10.1007/S11523-014-0349-2  0.314
2014 Pang YY, Yeo WK, Loh KY, Go ML, Ho HK. Structure-toxicity relationship and structure-activity relationship study of 2-phenylaminophenylacetic acid derived compounds. Food and Chemical Toxicology : An International Journal Published For the British Industrial Biological Research Association. 71: 207-16. PMID 24953550 DOI: 10.1016/J.Fct.2014.06.013  0.329
2014 Teo YL, Chong XJ, Chue XP, Chau NM, Tan MH, Kanesvaran R, Wee HL, Ho HK, Chan A. Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: In vitro, in vivo, and outcomes investigation Cancer Chemotherapy and Pharmacology. 73: 381-388. PMID 24306119 DOI: 10.1007/S00280-013-2360-1  0.31
2014 Yoong SL, Wong BS, Zhou QL, Chin CF, Li J, Venkatesan T, Ho HK, Yu V, Ang WH, Pastorin G. Enhanced cytotoxicity to cancer cells by mitochondria-targeting MWCNTs containing platinum(IV) prodrug of cisplatin. Biomaterials. 35: 748-59. PMID 24140044 DOI: 10.1016/J.Biomaterials.2013.09.036  0.313
2014 Kanesvaran R, Teo YL, Chue XP, Chau N, Tan M, Wee HL, Ho HK, Chan A. Association between clinical response and toxicities with drug exposure in an alternative dosing regimen of sunitinib. Journal of Clinical Oncology. 32: 439-439. DOI: 10.1200/Jco.2014.32.4_Suppl.439  0.313
2013 Ho HK, Németh G, Ng YR, Pang E, Szántai-Kis C, Zsákai L, Breza N, Greff Z, Horváth Z, Pató J, Szabadkai I, Szokol B, Baska F, Őrfî L, Ullrich A, et al. Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing. Current Medicinal Chemistry. 20: 1203-17. PMID 23409720 DOI: 10.2174/0929867311320100001  0.347
2013 Phua LC, Mal M, Koh PK, Cheah PY, Chan ECY, Ho HK. Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy Cancer Chemotherapy and Pharmacology. 71: 817-823. PMID 23271323 DOI: 10.1007/S00280-012-2054-0  0.303
2013 Ng T, Cheung YT, Ham Guo MS, Kee YC, Ho HK, Fan G, Yong WS, Madhukumar P, Ooi WS, Chay WY, Ng RC, Ng QS, Ang SF, Lo SK, Yap YS, et al. Plasma vascular endothelial growth factor level and cognitive changes in breast cancer patients. Journal of Clinical Oncology. 31: e20566-e20566. DOI: 10.1200/Jco.2013.31.15_Suppl.E20566  0.303
2013 Teo YL, Chue XP, Chau N, Tan M, Kanesvaran R, Wee HL, Ho HK, Chan A. Association of drug exposure with clinical response and toxicities in metastatic renal cell carcinoma patients (mRCC) receiving an alternative dosing (AD) regimen of sunitinib. Journal of Clinical Oncology. 31: e13582-e13582. DOI: 10.1200/Jco.2013.31.15_Suppl.E13582  0.317
2012 Saha S, Chan DS, Lee CY, Wong W, New LS, Chui WK, Yap CW, Chan EC, Ho HK. Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties. European Journal of Pharmacology. 697: 13-23. PMID 23041271 DOI: 10.1016/J.Ejphar.2012.09.021  0.337
2012 Chng HT, Ho HK, Yap CW, Lam SH, Chan EC. An investigation of the bioactivation potential and metabolism profile of Zebrafish versus human. Journal of Biomolecular Screening. 17: 974-86. PMID 22644267 DOI: 10.1177/1087057112447305  0.303
2012 Chan EC, New LS, Chua TB, Yap CW, Ho HK, Nelson SD. Interaction of lapatinib with cytochrome P450 3A5. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 1414-22. PMID 22511346 DOI: 10.1124/Dmd.112.044958  0.508
2012 Teo YL, Saetaew M, Chanthawong S, Yap YS, Yong Chan EC, Ho HK, Chan A. Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: Clinical and in vitro evidence Breast Cancer Research and Treatment. 133: 703-711. PMID 22370628 DOI: 10.1007/S10549-012-1995-7  0.35
2010 Teng WC, Oh JW, New LS, Wahlin MD, Nelson SD, Ho HK, Chan EC. Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Molecular Pharmacology. 78: 693-703. PMID 20624855 DOI: 10.1124/Mol.110.065839  0.527
2010 Saha S, New LS, Ho HK, Chui WK, Chan EC. Direct toxicity effects of sulfo-conjugated troglitazone on human hepatocytes. Toxicology Letters. 195: 135-41. PMID 20307632 DOI: 10.1016/J.Toxlet.2010.03.010  0.364
2010 Roidl A, Foo P, Wong W, Mann C, Bechtold S, Berger HJ, Streit S, Ruhe JE, Hart S, Ullrich A, Ho HK. The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells. Oncogene. 29: 1543-52. PMID 19946327 DOI: 10.1038/Onc.2009.432  0.306
2010 Saha S, New LS, Ho HK, Chui WK, Chan EC. Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity. Toxicology Letters. 192: 141-9. PMID 19854250 DOI: 10.1016/J.Toxlet.2009.10.014  0.338
2009 Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS, Loo HL, Aung MO, Lim SG, Ullrich A. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention Journal of Hepatology. 50: 118-127. PMID 19008009 DOI: 10.1016/J.Jhep.2008.08.015  0.301
2007 Ruhe JE, Streit S, Hart S, Wong CH, Specht K, Knyazev P, Knyazeva T, Tay LS, Loo HL, Foo P, Wong W, Pok S, Lim SJ, Ong H, Luo M, ... Ho HK, et al. Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Research. 67: 11368-76. PMID 18056464 DOI: 10.1158/0008-5472.Can-07-2703  0.315
2007 Coe KJ, Jia Y, Ho HK, Rademacher P, Bammler TK, Beyer RP, Farin FM, Woodke L, Plymate SR, Fausto N, Nelson SD. Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screening. Chemical Research in Toxicology. 20: 1277-90. PMID 17702527 DOI: 10.1021/Tx7001349  0.524
2006 Boelsterli UA, Ho HK, Zhou S, Leow KY. Bioactivation and hepatotoxicity of nitroaromatic drugs Current Drug Metabolism. 7: 715-727. PMID 17073576 DOI: 10.2174/138920006778520606  0.332
2006 Ho HK, Jia Y, Coe KJ, Gao Q, Doneanu CE, Hu Z, Bammler TK, Beyer RP, Fausto N, Bruschi SA, Nelson SD. Cytosolic heat shock proteins and heme oxygenase-1 are preferentially induced in response to specific and localized intramitochondrial damage by tetrafluoroethylcysteine. Biochemical Pharmacology. 72: 80-90. PMID 16678137 DOI: 10.1016/J.Bcp.2006.03.019  0.479
2005 Ho HK, White CC, Fernandez C, Fausto N, Kavanagh TJ, Nelson SD, Bruschi SA. Nrf2 activation involves an oxidative-stress independent pathway in tetrafluoroethylcysteine-induced cytotoxicity. Toxicological Sciences : An Official Journal of the Society of Toxicology. 86: 354-64. PMID 15901913 DOI: 10.1093/Toxsci/Kfi205  0.507
2005 Ho HK, Hu ZH, Tzung SP, Hockenbery DM, Fausto N, Nelson SD, Bruschi SA. BCL-xL overexpression effectively protects against tetrafluoroethylcysteine-induced intramitochondrial damage and cell death. Biochemical Pharmacology. 69: 147-57. PMID 15588723 DOI: 10.1016/J.Bcp.2004.08.030  0.501
Show low-probability matches.